�At the 1st World Congress for Interventional Therapies for Type 2 Diabetes, prominent endocrinologists from around the populace will convene in an exchange with leading surgeons about the role of surgery and other rising new therapies for type 2 diabetes.
Twenty-four of the most significant Scientific Societies from the US and worldwide have endorsed the World Congress to encourage a responsible and seasonable discussion of all aspects of this emerging discipline, including its implications for public health and diabetes research.
"The American Association of Clinical Endocrinologists (AACE) is pleased to endorse the 1st World Congress on Interventional Therapies for Type 2 Diabetes" the Society said in a assertion. "AACE recognizes the need for interventions that ar proven to be secure and effective in the management of type 2 diabetes. AACE looks onward to active in this very important scientific encounter, which will critically probe the potentiality role for surgery in treating type 2 diabetes and other related metabolic disorders."
"I am excited virtually the collaboration between endocrinologists and surgeons," said Dr. Louis Aronne clinical professor of medicine at Weill Cornell Medical College. "Together along with other leading experts in diabetes and public health, the Congress will examine the emergent role of surgery, not only as a therapy for type 2 diabetes, but as a means to molt light on the causes of the disease. The lessons we are already learning from studying gI surgery experience tremendous implications for the same future of medical therapies of diabetes."
Type 2 Diabetes affects an estimated 24 zillion Americans and 246 gazillion people worldwide, a number that is expected to grow to 380 billion by 2025. Faced with the escalating global diabetes crisis, wellness care providers require potent tools for therapeutic interventions. Various types of surgery on the gastrointestinal tract constitute passing powerful options to help fight diabetes in patients with terrible obesity. The appropriate role of surgical process in the treatment of patients with type 2 diabetes has recently become a matter of intense scientific and public debate.
"Surgery has arrived like a comet across the sphere of diabetes and corpulency unexpected, brilliant, with majuscule promise for the succeeding," said Dr. Jesse Roth, Congress staff member, research worker, and diabetologist at the Feinstein Institute for Medical Research and the Albert Einstein College of Medicine of Yeshiva University in New York. "Teams of talented researchers are moving ahead to define the role of surgery in the treatment of both of these scourges."
Dr Francesco Rubino, Director of the World Congress and Chief of Metabolic Surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, emphasised that surgery offers likewise a unique opportunity to improve knowledge of the mechanisms of diabetes. "Teasing out the agents creditworthy for the beneficial personal effects of gI surgery on diabetes may lead to new discoveries and provide targets for new medications or even less trespassing interventional therapies."
1ST WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES
The 1st World Congress on Interventional Therapies for Type 2 Diabetes is a comprehensive and multidisciplinary forum where leaders in the worldwide health community will carry on an organized review and discussion of the in vogue scientific information and theories on the use of bariatric surgery for the treatment of type 2 diabetes. The Congress, hosted by Weill Cornell Medical College and NewYork-Presbyterian Hospital, aims to create a forum for the medical community to work with health policy makers, including top public health government and insurers from the U.S. and around the world. The overarching drive is to craft an agenda of health policy initiatives to seize the opportunity offered by gastrointestinal surgery and novel interventional therapies for the understanding and treatment of diabetes. For more information, chew the fat http://www.interventionaldiabetology.org.
NewYork-Presbyterian Hospital
425 E 61st St., Fl. 7
New York, NY 10021
United States
http://www.nyp.org
More information
Thursday 4 September 2008
Monday 25 August 2008
Britney Spears & Justin Timberlake To Collaborate?
Britney Spears will collaborate with her former lover Justin Timberlake on her new album, say reports.
The 'Toxic' isaac M. Singer is currently recording the follow-up to her 2007 LP 'Blackout', scheduled for release in early 2009.
PageSix (the gossipmonger page of the New York Post) now reports the two are recording a duo at last, after a failed collaboration for 'Blackout' failed to come about.
The two were romantically joined between 1998 and 2002.
More info
Friday 15 August 2008
1 In 5 Young Men Has Had Recent Prostate Cancer Test
�A new analysis finds that one in five men in their 40s has had a prostate specific antigen (PSA) test within the previous year and that young black men are more likely than young white men to have undergone the test. The study, published in the September 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, provides valuable information as experts discuss possible changes to prostate cancer screening recommendations.
Currently, major medical organizations say evidence is insufficient to recommend routine prostate cancer screening using PSA or digital rectal exam (DRE). Rather, most group recommended men at average risk discuss with their doctor starting at age 50 whether to get tested. The American Cancer Society does though recommend that African Americans and men with a first degree relative with prostate cancer should , have screening every year, begin at age 45, and that men with two or more first degree relatives with prostate cancer begin testing at age 40.
To shed light on current PSA screening practices in young men, Dr. Judd Moul and Dr. Charles Scales, of Duke Prostate Center and Urologic Surgery at Duke University and colleagues obtained data from the 2002 Behavioral Risk Factor Surveillance System, an annual, population-based survey of civilian, non-institutionalized adults in the United States. The final sample for this study consisted of 58,511 men ages 40 and above.
The investigators found that one in five of them men had undergone screening in the previous year. Several sociodemographic characteristics were associated with PSA screening in younger men. In particular, young, black, non-Hispanic men were more likely than young white, non-Hispanic men to report having a PSA test in the previous year. This finding was independent of income, education and access to care. The authors noted that these results are reassuring, showing that physicians are more likely to recommend screening among black men due to this group's elevated risk for prostate cancer. However, they also noted that PSA screening in this group remains potentially suboptimal; only about one in three African American men reported having a PSA test in the previous year.
The survey also revealed that younger Hispanic men were more likely to undergo PSA testing than younger white, non-Hispanic men. The probability of undergoing a PSA test was also higher with increasing obesity, as well as with higher household income and education level. Health insurance coverage and an ongoing relationship with a physician were also strongly associated with having had a recent PSA test.
"Our study is the first to specifically examine PSA screening in younger men, which provides an important assessment of quality of care, especially for high-risk groups," the authors write. "Further investigation will be required to understand the impact of new risk-stratification strategies, with particular focus on the policy implications of potentially large increases in health care resource use".
"Prostate-Specific Antigen screening among young men in the United States."
Charles D. Scales, Jr, Jodi Antonelli, Lesley H. Curtis, Kevin A. Schulman, and Judd W. Moul.
CANCER; Published Online: August 11, 2008 (DOI: 10.1002/cncr23667); Print Issue Date: September 15, 2008.
Wiley-Blackwell
More info
Currently, major medical organizations say evidence is insufficient to recommend routine prostate cancer screening using PSA or digital rectal exam (DRE). Rather, most group recommended men at average risk discuss with their doctor starting at age 50 whether to get tested. The American Cancer Society does though recommend that African Americans and men with a first degree relative with prostate cancer should , have screening every year, begin at age 45, and that men with two or more first degree relatives with prostate cancer begin testing at age 40.
To shed light on current PSA screening practices in young men, Dr. Judd Moul and Dr. Charles Scales, of Duke Prostate Center and Urologic Surgery at Duke University and colleagues obtained data from the 2002 Behavioral Risk Factor Surveillance System, an annual, population-based survey of civilian, non-institutionalized adults in the United States. The final sample for this study consisted of 58,511 men ages 40 and above.
The investigators found that one in five of them men had undergone screening in the previous year. Several sociodemographic characteristics were associated with PSA screening in younger men. In particular, young, black, non-Hispanic men were more likely than young white, non-Hispanic men to report having a PSA test in the previous year. This finding was independent of income, education and access to care. The authors noted that these results are reassuring, showing that physicians are more likely to recommend screening among black men due to this group's elevated risk for prostate cancer. However, they also noted that PSA screening in this group remains potentially suboptimal; only about one in three African American men reported having a PSA test in the previous year.
The survey also revealed that younger Hispanic men were more likely to undergo PSA testing than younger white, non-Hispanic men. The probability of undergoing a PSA test was also higher with increasing obesity, as well as with higher household income and education level. Health insurance coverage and an ongoing relationship with a physician were also strongly associated with having had a recent PSA test.
"Our study is the first to specifically examine PSA screening in younger men, which provides an important assessment of quality of care, especially for high-risk groups," the authors write. "Further investigation will be required to understand the impact of new risk-stratification strategies, with particular focus on the policy implications of potentially large increases in health care resource use".
"Prostate-Specific Antigen screening among young men in the United States."
Charles D. Scales, Jr, Jodi Antonelli, Lesley H. Curtis, Kevin A. Schulman, and Judd W. Moul.
CANCER; Published Online: August 11, 2008 (DOI: 10.1002/cncr23667); Print Issue Date: September 15, 2008.
Wiley-Blackwell
More info
Thursday 7 August 2008
Zorch
Artist: Zorch
Genre(s):
Electronic
Discography:
Ouroboros
Year: 2001
Tracks: 6
Glastonbury Live
Year: 2000
Tracks: 8
Friday 27 June 2008
Coldplay Accused Of 'Copying Viva La Vida Melody'
An American indie band have accused Coldplay of copying the melody from one of their songs and using it on the band's new album.
Creaky Boards claim that 'Viva La Vida', the title track from Coldplay's number one album, takes its melody from a track that's ironically entitled 'The Songs I didn't Write'.
In a video message on YouTube, Andrew Hoepfner, the bands songwriter, says that Martin even saw the band when they performed last year.
"We were flattered when we thought we saw Chris Martin in the crowd that night. He seemed pretty into it. Maybe too into it,” he writes.
'Viva La Vida' went straight in at number one yesterday (June 15th), selling 302,000 copies in just three days.
Coldplay, who will perform in London later today (June 16th), have yet to respond to the claims.
What do you think about the accusations? Watch the video below and then post a comment.
Sign up and your comments will be approved automatically.
See Also
Monday 16 June 2008
Kooks: 'We'll Conquer America -- Unlike the Arctic Monkeys'
Kooks frontman Luke Pritchard has vowed his band will conquer America � unlike their chart rivals Arctic Monkeys.
Luke said the band's second album Konk was doing really well stateside, whereas the Arctics' popularity has plummeted.
The band, whose debut album Inside In/Inside Out has sold more than a million copies and attained triple platinum status, have just finished touring America and things are looking so good that Luke is splashing out on a New York pad.
He revealed, "It's really going great over there. Radio is really picking up on the album.
"Arctic Monkeys have just died over there. They were huge for their first album but it hasn�t happened with the second one."
See Also
Subscribe to:
Posts (Atom)